What is ViAqua Therapeutics?
Headquartered in Haifa, Israel, ViAqua Therapeutics is a pioneering biotechnology firm dedicated to revolutionizing health management within the aquaculture sector. The company specializes in the development of an innovative oral delivery platform designed to administer nucleic acid-based solutions to marine species. This technology addresses one of the most significant hurdles in modern aquaculture: the effective, specific, and affordable treatment of diseases that threaten global food security.
By focusing on scalable, biotechnology-driven interventions, ViAqua occupies a unique niche at the intersection of marine biology and pharmaceutical development. Its market position is strengthened by a commitment to sustainable practices, aligning with the broader global shift toward environmentally responsible protein production. The company's platform serves as a critical tool for producers seeking to mitigate biological risks while maintaining high standards of animal welfare and operational efficiency.
How much funding has ViAqua Therapeutics raised?
ViAqua Therapeutics has raised a total of $12.6M across 2 funding rounds:
Other Financing Round
$4.3M
Other Financing Round
$8.3M
Other Financing Round (2021): $4.3M with participation from Technion Israel Institute of Technology, Nutreco, VisVires New Protein, Thai Union, Agriline Products, S2G Ventures, and The Trendlines Group
Other Financing Round (2023): $8.3M led by S2G Ventures and Rabo Frontier Ventures
Key Investors in ViAqua Therapeutics
S2G Ventures
S2G Ventures is a multi-stage food and agriculture venture fund that invests in entrepreneurs building sustainable solutions across the entire food supply chain.
Rabo Frontier Ventures
RFV is the investment arm of Rabobank, focusing on early-growth stage fintech and agtech companies that disrupt or influence the global food and agriculture sectors.
VisVires New Protein
VisVires New Protein is a venture capital firm dedicated to backing transformative, sustainable solutions within the global agri-food system.
What's next for ViAqua Therapeutics?
With the successful closure of this major enterprise-level funding round, ViAqua Therapeutics is well-positioned to accelerate the commercialization of its oral delivery platform. The strategic capital will likely be deployed to scale manufacturing capabilities, expand clinical validation across diverse marine species, and strengthen its intellectual property portfolio. As the company transitions into a more mature operational phase, the focus will shift toward broad-market adoption and the integration of its solutions into the global aquaculture supply chain.
The continued support from specialized agtech investors suggests a long-term commitment to establishing ViAqua as a standard-bearer for marine health technology. Future milestones will likely include regulatory approvals in key international markets and the expansion of its therapeutic pipeline to address a wider array of aquatic pathogens, further cementing its influence in the sustainable food technology ecosystem.
